Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Dolman

Showing results (141-150 of 165) with videos related to

Pageof 17
Sort By:
Ebiomedicine|August 27, 2020
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastomaSally L George, Federica Lorenzi, David King, et al.
BMC Cancer|April 5, 2023
The potential of PARP as a therapeutic target across pediatric solid malignanciesKaylee M Keller, Joost Koetsier, Linda Schild, et al.
JAMA|November 8, 2011
Factors associated with treatment response to etanercept in juvenile idiopathic arthritisMarieke H Otten, Femke H M Prince, Wineke Armbrust, et al.
Cell Reports|August 25, 2021
Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumorsCamilla Calandrini, Sander R van Hooff, Irene Paassen, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 4, 2021
Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastomaMarlinde L van den Boogaard, Rurika Oka, Anne Hakkert, et al.
The Journal of Rheumatology|August 17, 2011
Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010Marieke H Otten, Femke H M Prince, Marinka Twilt, et al.
Arthritis Research & Therapy|August 8, 2015
MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritisJanneke Anink, Lisette W A Van Suijlekom-Smit, Marieke H Otten, et al.
Ecology Letters|August 6, 2013
Reliable, verifiable and efficient monitoring of biodiversity via metabarcodingYinqiu Ji, Louise Ashton, Scott M Pedley, et al.
Annals of the Rheumatic Diseases|November 12, 2010
Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?Marieke H Otten, Femke H M Prince, Rebecca Ten Cate, et al.
Rheumatology (Oxford, England)|January 7, 2020
MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritisAnouk M Barendregt, Saskia R Veldkamp, Petra C E Hissink Muller, et al.
Pageof 17

Showing results (141-150 of 165) with videos related to

Sort By:
Pageof 17
Ebiomedicine|August 27, 2020
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastomaSally L George, Federica Lorenzi, David King, et al.
BMC Cancer|April 5, 2023
The potential of PARP as a therapeutic target across pediatric solid malignanciesKaylee M Keller, Joost Koetsier, Linda Schild, et al.
JAMA|November 8, 2011
Factors associated with treatment response to etanercept in juvenile idiopathic arthritisMarieke H Otten, Femke H M Prince, Wineke Armbrust, et al.
Cell Reports|August 25, 2021
Organoid-based drug screening reveals neddylation as therapeutic target for malignant rhabdoid tumorsCamilla Calandrini, Sander R van Hooff, Irene Paassen, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 4, 2021
Defects in 8-oxo-guanine repair pathway cause high frequency of C > A substitutions in neuroblastomaMarlinde L van den Boogaard, Rurika Oka, Anne Hakkert, et al.
The Journal of Rheumatology|August 17, 2011
Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010Marieke H Otten, Femke H M Prince, Marinka Twilt, et al.
Arthritis Research & Therapy|August 8, 2015
MRP8/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritisJanneke Anink, Lisette W A Van Suijlekom-Smit, Marieke H Otten, et al.
Ecology Letters|August 6, 2013
Reliable, verifiable and efficient monitoring of biodiversity via metabarcodingYinqiu Ji, Louise Ashton, Scott M Pedley, et al.
Annals of the Rheumatic Diseases|November 12, 2010
Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?Marieke H Otten, Femke H M Prince, Rebecca Ten Cate, et al.
Rheumatology (Oxford, England)|January 7, 2020
MRP8/14 and neutrophil elastase for predicting treatment response and occurrence of flare in patients with juvenile idiopathic arthritisAnouk M Barendregt, Saskia R Veldkamp, Petra C E Hissink Muller, et al.
Pageof 17